Malerba Medica SRL
Malerba Medica reported total assets of 793,041 € at the end of the 2025 financial year (annual accounts filed with the NBB on 27 Jul 2026).
By total assets for 2025, Malerba Medica ranks among the 5,000 largest of the 15,434 companies in its sector (NACE 8622) in Belgium that filed accounts for that financial year. Largest companies in the sector →
The score of Malerba Medica shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2023 → 2025: Equity +6503 % Total assets +5855 %
Accounts of the company itself (not consolidated).
The full file covers 3 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Malerba Medica's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 27 Jul 2026
- Year ended 31 Dec 2024filed on 18 Aug 2025
- Year ended 31 Dec 2023filed on 26 Aug 2024
Malerba Medica's financial analysis
- Solvency74.9%sector median: 67.6%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Malerba Medica
Malerba Medica's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1002.812.229
- VAT number
- BE1002812229
- Peppol
- Registered · 0208:1002812229 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 29 Nov 2023
- Registered office
- 1050 Ixelles
- Latest accounts
- 2025 · filed on 27 Jul 2026
- Activity
- Medical specialists activities (NACE 86220)
Malerba Medica (SRL) has been based in Ixelles since 2023, active in: medical specialists activities. For 2025, it reports a net profit of 311,857 € and equity of 593,797 €; its revenue is not published. Its solvency stands at 74.9%, above the median of its sector (67.6%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Malerba Medica
Companies in the same business, of comparable size and area, outside its group.
- Vandef Manufacture of carpets and rugs Waregem · balance sheet 792,944 €
- Orbit Energy All other professional, scientific and technical activities n.e.c. Etterbeek · balance sheet 792,491 €
- Medimad Public relations and communication activities Brussels · balance sheet 793,860 €
- Rainbow Activities Manufacture of basic pharmaceutical products Ghent · balance sheet 792,066 €
- PATRIMONIUM 't ZAND Koksijde · balance sheet 793,304 €
- DR.de Beule D. Sint-Gillis-Waas · balance sheet 792,556 €
- Ghilain JM Ciney · balance sheet 792,497 €
Frequently asked questions about Malerba Medica
What is the revenue of Malerba Medica?
Malerba Medica files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Malerba Medica?
In Belgium, the VAT number is the company number prefixed with BE: BE1002812229 for Malerba Medica, if the company is VAT-registered. Its company number (CBE) is 1002.812.229.
Where is the registered office of Malerba Medica?
According to the CBE register, the registered office of Malerba Medica is in 1050 Ixelles.
What is the equity of Malerba Medica?
At the close of the 2025 financial year, the equity of Malerba Medica amounts to 593,797 €, a solvency of 74.9% of total assets.
Who manages Malerba Medica?
The register lists 1 active mandates at Malerba Medica. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
How large is Malerba Medica within its sector?
By total assets for 2025, Malerba Medica ranks among the 5,000 largest of the 15,434 companies in its sector (NACE 8622) in Belgium that filed accounts for that financial year.
The full file of Malerba Medica
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →